Vnitr Lek 2015, 61(4):361-364

The microbial flora in the digestive tract and diabetes

Štěpán Svačina
III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

The microbial flora in the digestive tract has been recently studied in relation to metabolic diseases. There are relations to both type 1 diabetes and type 2 diabetes. The intestinal flora is affected by diet, physical exercise and it significantly changes after bariatric surgeries. Giving birth by caesarean section affects the gut flora development and increases the risk of type 1 diabetes in further life of the child. Obese patients with type 2 diabetes may lack protective microbes which improve glucoregulation in the experiment or on the contrary their patogenous microbes may grow which have been proven to even be able to penetrate into abdominal adipose tissue and play a role, inter alia, in the hepatic impairment and systemic inflammation. Also vaccination against these microbes is under consideration. Microbiome can be also positively affected by metformin treatment. The transfer of intestinal flora by means of fecal transplantation can improve glucoregulation. The influencing of intestinal flora is likely to become a new mechanism of diabetes treatment.

Keywords: type 1 diabetes; type 2 diabetes; metformin; microbiome; obesity; risk of diabetes; fecal transplantation; adipose tissue; vaccination

Received: March 15, 2015; Accepted: March 23, 2015; Published: April 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. The microbial flora in the digestive tract and diabetes. Vnitr Lek. 2015;61(4):361-364.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Relman DA. Microbiology: Learning about who we are. Nature 2012; 486(7402): 194-195. Go to original source... Go to PubMed...
    2. Institute of Medicine (US) Food Forum: The Human Microbiome, Diet, and Health. Workshop Summary. National Academies Press (US): Washington (DC) 2013. ISBN 978-0-309-26585-0.
    3. Fernández L, Langa S, Martín V et al. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res 2013; 69(1): 1-10. Go to original source... Go to PubMed...
    4. Latuga MS, Stuebe A, Seed PC. A review of the source and function of microbiota in breast milk. Semin Reprod Med 2014; 32(1): 68-73. Go to original source... Go to PubMed...
    5. Svačina Š. Prevence diabetu a jeho komplikací. Triton: Praha 2008. ISBN 978-80-7387-178-9.
    6. Khashan AS, Kenny LC, Lundholm C et al. Mode of obstetrical delivery and type 1 diabetes: a sibling design study. Pediatrics 2014; 134(3): e806-e813. Dostupné z DOI: <http://doi:10.1542/peds.2014-0819>. Go to original source... Go to PubMed...
    7. Vaarala O. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol 2008; 24(6): 701-706. Go to original source... Go to PubMed...
    8. Dunne JL, Triplett EW, Gevers D et al. The intestinal microbiome in type 1 diabetes. Clin Exp Immunol 2014; 177(1): 30-37. Go to original source... Go to PubMed...
    9. Remely M, Aumueller E, Jahn D. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 2014; 5(1): 33-43. Go to original source... Go to PubMed...
    10. Fried M (ed). Bariatrická a metabolická chirurgie: nové postupy v léčbě obezity a metabolických poruch. Mladá Fronta: Praha 2011. ISBN 978-80-204-2424-2.
    11. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Mladá Fronta: Praha 2010. ISBN 978-80-204-2247-7.
    12. Udayappan SD, Hartstra AV, Dallinga-Thie GM et al. Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. Clin Exp Immunol 2014; 177(1): 24-29. Go to original source... Go to PubMed...
    13. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110(22): 9066-9071. Go to original source... Go to PubMed...
    14. Cani PD, Everard A. Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation? Med Sci (Paris) 2014; 30(2): 125-127. Go to original source... Go to PubMed...
    15. Napolitano A, Miller S, Nicholls AW et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014; 9(7): e100778. Dostupné z DOI: <http://doi:10.1371/journal.pone.0100778>. Go to original source... Go to PubMed...
    16. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 2014; 63(9): 1513-1521. Go to original source... Go to PubMed...
    17. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143(4): 913-916. Go to original source... Go to PubMed...
    18. Amar J, Chabo C, Waget A et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3(9): 559-572. Go to original source... Go to PubMed...
    19. Nieuwdorp M et al. The therapeutic potential of manipulating gut microbionta in obesity and type 2 diabetes. Zvaná přednáška na EASD 2014 Vídeň září 2014. Ústní sdělení, dosud nepublikováno.
    20. Petriz BA, Castro AP, Almeida JA et al. Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats. BMC Genomics 2014; 15: 511. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2164-15-511>. Go to original source... Go to PubMed...
    21. Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463. Go to original source... Go to PubMed...
    22. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013; 24(11): 537-545. Go to original source... Go to PubMed...
    23. Bleau C, Karelis AD, St-Pierre DH et al. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev 2014; e-pub. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2617>. Go to original source... Go to PubMed...
    24. Konrad D, Wueest S. The gut-adipose-liver axis in the metabolic syndrome. Physiology (Bethesda) 2014; 29(5): 304-313. Go to original source... Go to PubMed...
    25. Bleau C, Karelis AD, St-Pierre DH et al. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev 2014; e-publikace. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2617>. Go to original source... Go to PubMed...
    26. Greenhill C. Gut microbiota: not so sweet - artificial sweeteners can cause glucose intolerance by affecting the gut microbiota. Nat Rev Endocrinol 2014; 10(11): 637. Go to original source... Go to PubMed...
    27. Kim MS, Hwang SS, Park EJ et al. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013; 5(5): 765-775. Go to original source... Go to PubMed...
    28. Pekkala S, Munukka E, Kong L et al. Toll-like receptor 5 in obesity: The role of gut microbiota and adipose tissue inflammation. Obesity (Silver Spring) 2015; 23(3): 581-590. Go to original source... Go to PubMed...
    29. Pluznick J A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 2014; 5(2): 202-207. Go to original source... Go to PubMed...
    30. Svačina Š. Obezitologie a teorie metabolického syndromu. Triton: Praha 2013. ISBN 978-80-7387-678-4.
    31. Bäckhed F, Manchester JK, Semenkovich CF et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3): 979-984. Go to original source... Go to PubMed...
    32. Moghadamrad S, McCoy KD, Geuking MB et al. Attenuated portal hypertension in germ-free mice: Function of bacterial flora on the development of mesenteric lymphatic and blood vessels. Hepatology 2015; e-publikace v tisku. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.27698>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.